SCHEMBL301165

SCHEMBL301165

CCc1ccccc1-n1c(=O)[nH]c2c(C(N)=O)nc(-c3cccc(O)c3)nc21

nearest known ligand 0.67

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 15/20 0.67
PIK3CB P42338 15/20 0.67
PIK3CG P48736 15/20 0.67
PIK3CA P42336 14/20 0.67
KDM4E B2RXH2 2/20 0.61
GLA P06280 2/20 0.61
ALDH1A1 P00352 1/20 0.61
GAA P10253 1/20 0.61
HPGD P15428 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
CSNK2A1 P68400 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL300991 0.92 PIK3CD (0.62) PIK3CDPIK3CBPIK3CGPIK3CAKDM4E
SCHEMBL293199 0.89 PIK3CD (0.68) PIK3CDPIK3CBPIK3CGPIK3CAKDM4E
SCHEMBL301171 0.88 PIK3CD (0.75) PIK3CDPIK3CBPIK3CGPIK3CAKDM4E
SCHEMBL300978 0.87 PIK3CD (0.68) PIK3CDPIK3CBPIK3CGPIK3CAKDM4E
SCHEMBL301307 0.87 PIK3CD (0.68) PIK3CDPIK3CBPIK3CGPIK3CAKDM4E
SCHEMBL29793901 0.87 PIK3CD (0.65) PIK3CDPIK3CBPIK3CGPIK3CAKDM4E
SCHEMBL30662742 0.87 PIK3CD (0.65) PIK3CDPIK3CBPIK3CGPIK3CAKDM4E
SCHEMBL300821 0.87 PIK3CD (0.65) PIK3CDPIK3CBPIK3CGPIK3CAKDM4E
SCHEMBL301173 0.87 PIK3CD (0.65) PIK3CDPIK3CBPIK3CGPIK3CAKDM4E
SCHEMBL301340 0.85 PIK3CD (0.68) PIK3CDPIK3CBPIK3CGPIK3CAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101679432-B Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors SIGNAL PHARM LLC 2015-04-22 CN claimed
EP-2078018-B1 HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS SIGNAL PHARM LLC (US) 2012-03-14 EP claimed
CN-107976546-B Inhibition of phosphorylation of TOR kinase inhibitory Activity markers PRAS40, GSK 3-beta, or P70S6K1 西格诺药品有限公司 2020-10-27 CN disclosed
CN-110721186-A Treatment of prostate cancer with TOR kinase inhibitors 西格诺药品有限公司 2020-01-24 CN disclosed
CN-107157990-B Treatment of cancer with TOR kinase inhibitors 西格诺药品有限公司 2020-01-07 CN disclosed
CN-109846884-A With TOR kinase inhibitor for treating cancer 西格诺药品有限公司 2019-06-07 CN disclosed
CN-105039520-A Identification of gene expression profile as a predictive biomarker for lkb1 status SIGNAL PHARM LLC 2015-11-11 CN disclosed
CN-101679432-B Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors SIGNAL PHARM LLC 2015-04-22 CN disclosed
CN-104271139-A Treatment of cancer with tor kinase inhibitors SIGNAL PHARM LLC 2015-01-07 CN disclosed
CN-104271138-A Treatment of cancer with tor kinase inhibitors SIGNAL PHARM LLC 2015-01-07 CN disclosed
CN-103857804-A Identification of gene expression profiles as predictive biomarkers for LKB1 status SIGNAL PHARM LLC 2014-06-11 CN disclosed
CN-102821767-A IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS SIGNAL PHARM LLC 2012-12-12 CN disclosed
CN-101679432-A Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors SIGNAL PHARM LLC 2010-03-24 CN disclosed